Evidence map›Paper›PMID 21470203›Full record

ArticleBritish journal of pharmacology2012

The cannabinoid CB1 receptor antagonists rimonabant (SR141716) and AM251 directly potentiate GABA(A) receptors.

R Baur, J Gertsch, E Sigel

Open access · bronzeAbstract read
In one paragraph

Article in British journal of pharmacology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 1 pooled it
3.3field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 1 synthesis or guideline pooled it, 40 citations in OpenAlex.

  1. Cys-loop receptors on cannabinoids: All high?Frontiers in physiology · 2022
    Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Effects of Cannabinoid Agonists and Antagonists on Sleep in Laboratory Animals.Advances in experimental medicine and biology · 2021
    Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Sigma receptors [σRs]: biology in normal and diseased states.Journal of receptor and signal transduction research · 2016
    Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

R BaurInstitute of Biochemistry and Molecular Medicine, University of Bern, Bühlstr, Bern, Switzerland.
J Gertsch
E Sigel
University of Bern · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

background and purposeRimonabant (SR141716) and the structurally related AM251 are widely used in pharmacological experiments as selective cannabinoid receptor CB(1) antagonists / inverse agonists. Concentrations of 0.5-10 µM are usually applied in in vitro experiments. We intended to show that these drugs did not act at GABA(A) receptors but found a significant positive allosteric modulation instead. EXPERIMENTAL APPROACH: Recombinant GABA(A) receptors were expressed in Xenopus oocytes. Receptors were exposed to AM251 or rimonabant in the absence and presence of GABA. Standard electrophysiological techniques were used to monitor the elicited ionic currents. KEY

resultsAM251 dose-dependently potentiated responses to 0.5 µM GABA at the recombinant α(1) β(2) γ(2) GABA(A) receptor with an EC(50) below 1 µM and a maximal potentiation of about eightfold. The Hill coefficient indicated that more than one binding site for AM251 was located in this receptor. Rimonabant had a lower affinity, but a fourfold higher efficacy. AM251 potentiated also currents mediated by α(1) β(2) , α(x) β(2) γ(2) (x = 2,3,5,6), α(1) β(3) γ(2) and α(4) β(2) δ GABA(A) receptors, but not those mediated by α(1) β(1) γ(2) . Interestingly, the CB(1) receptor antagonists LY320135 and O-2050 did not significantly affect α(1) β(2) γ(2) GABA(A) receptor-mediated currents at concentrations of 1 µM. CONCLUSIONS AND IMPLICATIONS: This study identified rimonabant and AM251 as positive allosteric modulators of GABA(A) receptors. Thus, potential GABAergic effects of commonly used concentrations of these compounds should be considered in in vitro experiments, especially at extrasynaptic sites where GABA concentrations are low. LINKED ARTICLES: This article is part of a themed section on Cannabinoids in Biology and Medicine. To view the other articles in this section visit http://dx.doi.org/10.1111/bph.2012.165.issue-8. To view Part I of Cannabinoids in Biology and Medicine visit http://dx.doi.org/10.1111/bph.2011.163.issue-7.

Indexed as

AnimalsBenzofuransDronabinolgamma-Aminobutyric AcidOocytesPiperidinesPyransPyrazolesReceptor, Cannabinoid, CB1Receptors, GABA-ARecombinant ProteinsRimonabantXenopus(6aR,10aR)-3-(1-methansulfonylamino-4-hexyn-6-yl)6a,7,10,10a-tetrahydro-6,6,9-trimethyl-6H-dibenzo(b,d)pyranAM 251BenzofuransDronabinolgamma-Aminobutyric AcidLY 320135PiperidinesPyransPyrazolesReceptor, Cannabinoid, CB1Receptors, GABA-ARecombinant ProteinsRimonabant

Identifiers

PMID21470203
PMCPMC3423234
OpenAlexW1825405400

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.